MUC1 and cancer: To improve the immunogenicity of TAAs, Zhao et al. reported that a novel type of MUC1-FSL-1 conjugate as a self-adjuvanting (glyco)lipopeptide cancer vaccine could induce T-cell mediated responses capable of killing tumor cells (Liu et al., 2016).